We're not comparing apples and apples. Clinical studies for medical devices like XV tech is different from clinical studies for a new drug.
As you may know, XV tech has been cleared by the FDA and the TGA. So it's passed the stringent requirements for this.
The technology has been validated through commercial settings which is very valuable. If reputable organisations like the Uni of Miami has signed up for our tech after testing it extensively, it speaks volume.
We've also conducted plenty of clinical studies in recent years that have been presented at the ATS. More than a half of dozen of which were presented at ATS 2023.
Research, page-1871
-
- There are more pages in this discussion • 705 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add 4DX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
55.5¢ |
Change
-0.020(3.48%) |
Mkt cap ! $225.0M | |||
| Open | High | Low | Value | Volume |
| 58.0¢ | 58.5¢ | 54.0¢ | $218.3K | 388.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 5259 | 55.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 56.0¢ | 750 | 1 |
View Market Depth
| Last trade - 11.22am 24/06/2024 (20 minute delay) ? |
| 4DX (ASX) Chart |